Helicobacter pylori in Peptic Ulcer Disease

Helicobacter Pylori, Tadataka Yamada, John G. Searle, Dennis Ahnen, David H. Aipers, Harry B. Greenberg, Martha Gray, Kent B. Joscelyn, Kent B. McNair, Kent B. Jeffrey, Gordon Kauffman, Daniel K. Podolsky, Wayne A. Ray, Dennis Schaberg, Fred E. Silverstein, Michael V. Sivak, Ann L.B. Williams, Robert Yolken, Martin J. Blaser, Geron BorschPelayo Correa, Steven J. Czinn, David Forman, David Y. Graham, Jon L. Isenberg, Dennis M. Jensen, Barry J. Marshall, Julie Parsonnet, Walter L. Peterson, Pentti Sipponen, Duane Thomas Smoot, Andrew H. Soil, Amnon Sonnenberg, Nicholas J. Talley, W. Grant Thompson, G. N.J. Tytgat, John H. Walsh, T. Ulf Westblom, Kenneth G. Wormsley, Frank A. Hamilton, Addison B. Scoville, Benjamin T. Burton, Leslie Curtis, Jerry M. Elliott, James Everhart, John H. Ferguson, Willis R. Foster, William H. Hall, Jay H. Hoofnagle, Leslye D. Johnson, John Walsh, Phillip Gorden, Anthony S. Fauci

Research output: Contribution to journalArticle

Abstract

The National Institutes of Health Consensus Development Conference on Helicobacter pylori in Peptic Ulcer Disease brought together specialists in gastroenterology, surgery, infectious diseases, epidemiology, and pathology, as well as the public to address the following questions: (1) What is the causal relationship of H pylori to upper gastrointestinal disease? (2) How does one diagnose and eradicate H pylori infection? (3) Does eradication of H pylori infection benefit the patient with peptic ulcer disease? (4) What is the relationship between H pylori infection and gastric malignancy? (5) Which H pylori—infected patients should be treated? (6) What are the most important questions that must be addressed by future research in H pylori infections? Following 1½ days of presentations by experts and discussion by the audience, a consensus panel weighed the evidence and prepared their consensus statement. Among their findings, the consensus panel concluded that (1) ulcer patients with H pylori infection require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation with the illness or on recurrence; (2) the value of treating of nonulcerative dyspepsia patients with H pylori infection remains to be determined; and (3) the interesting relationship between H pylori infection and gastric cancers requires further exploration. (JAMA. 1994;272:65-69).

Original languageEnglish (US)
Pages (from-to)65-69
Number of pages5
JournalJAMA: The Journal of the American Medical Association
Volume272
Issue number1
DOIs
StatePublished - Jul 6 1994

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Helicobacter pylori in Peptic Ulcer Disease'. Together they form a unique fingerprint.

  • Cite this

    Pylori, H., Yamada, T., Searle, J. G., Ahnen, D., Aipers, D. H., Greenberg, H. B., Gray, M., Joscelyn, K. B., McNair, K. B., Jeffrey, K. B., Kauffman, G., Podolsky, D. K., Ray, W. A., Schaberg, D., Silverstein, F. E., Sivak, M. V., Williams, A. L. B., Yolken, R., Blaser, M. J., ... Fauci, A. S. (1994). Helicobacter pylori in Peptic Ulcer Disease. JAMA: The Journal of the American Medical Association, 272(1), 65-69. https://doi.org/10.1001/jama.1994.03520010077036